Analyst Price Targets — ANVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 16, 2024 6:56 am | Raghuram Selvaraju | H.C. Wainwright | $30.00 | $8.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Annovis Bio Inc. (ANVS) |
| August 13, 2024 7:05 am | Jason Kolbert | EF Hutton | $21.00 | $7.87 | TheFly | Annovis Bio initiated with a Buy at EF Hutton |
| April 30, 2024 7:34 am | Sumant Kulkarni | Canaccord Genuity | $26.00 | $7.28 | TheFly | Annovis Bio price target lowered to $26 from $36 at Canaccord |
Latest News for ANVS
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the…
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANVS.
U.S. House Trading
No House trades found for ANVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.